Novo Drops NovoSeven Stroke Program Following Phase III Failure
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Novo Nordisk announced Feb. 26 that it would not seek approval for use of NovoSeven (human recombinant factor VIIa) in intracerebral hemorrhage following negative efficacy findings in a Phase III study.